Invivyd names Chairman Marc Elia as CEO, adds board member ahead of VYD2311 data

Invivyd, Inc. announced on September 1, 2026 that its board appointed Marc Elia, Chairman of the Board, as the company's Chief Executive Officer, effective as of August 30, 2026¹. He takes over the principal executive officer role, a role previously held by William Duke, Jr., the company's Chief Financial Officer, who remains the company's principal financial officer and principal accounting officer¹.

In connection with the change, the board appointed Ajay Royan as the Lead Independent Director of the Board, effective as of the Effective Date¹. Separately, the board increased the size of the Board from six directors to seven directors and appointed Ian Sheffield as a director to fill the resulting vacancy, effective as of August 30, 2026, with his term expiring at the company's 2027 annual meeting of stockholders¹.

Under his employment agreement, Elia is set to receive an annual base salary of $750,000¹, an initial target annual bonus is 70% of his annual base salary¹, a one-time sign-on bonus of $500,000 as soon as practicable after the Effective Date¹, and an option to purchase 10,700,000 shares of the company's common stock at an exercise price equal to the closing sales price for the Common Stock as quoted on the Nasdaq Stock Market on August 28, 2026¹, vesting over four years.

On the clinical side, Invivyd said it continues to expect top-line data from the VYD2311 program around the end of Q3 2026¹. The company outlined two possible regulatory paths: to either unblind the DECLARATION study in its entirety and submit a Biologics License Application (BLA) towards traditional product approval, or partially unblind the study (leaving clinical events blinded) and submit a BLA towards Accelerated Approval on the basis of antiviral activity and safety, with greater statistical power expected to be achieved in a post-approval confirmatory clinical cohort¹. DECLARATION is a Phase 3, randomized, triple-blind, placebo-controlled trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents both with and without risk factors for progression to severe COVID-19 at three months, with total enrollment of approximately 2,400 participants¹. LIBERTY is a Phase 3, randomized, double-blind clinical trial evaluating safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311 alone and co-administered with an mRNA COVID vaccine, with enrollment of approximately 210 participants¹.